The prospect of Donald Trump imposing tariffs of up to 200% on imported generic medicines is increasingly being interpreted as a negotiating tactic rather than a concrete policy shift.
A commentary in Handelsblatt suggests the US president is employing his familiar strategy of issuing stark threats to secure a more favorable position in ongoing trade discussions, with little expectation that such extreme measures will be enacted.
The broader trade offensive follows the imposition of a temporary 10% global tariff, signaling a continued escalation in US trade policy.
The threat specifically targets the supply chain for off-patent drugs, a sector where Swiss pharmaceutical giant Sandoz holds significant exposure.
While the potential levy would have severe implications for global pharmaceutical logistics and pricing, market participants are weighing the rhetoric against the administration's historical pattern of using aggressive posturing to drive concessions from trading partners.
This development arrives as reports indicate the White House is preparing to announce a new round of tariffs on dozens of countries as early as this week.
The broader trade offensive follows the imposition of a temporary 10% global tariff, signaling a continued escalation in US trade policy.